UnitedHealth Group (NYSE: UNH)

The call

We are initiating on UnitedHealth Group with a HOLD and a $400 fair value.

At the 52-week low of $255.97 this was an obvious buy. It closed Friday at $397.14, up more than half from that low, and the argument has changed completely. What is left to earn requires a commercial margin recovery that management itself says will take longer than expected.

Our normalized earnings estimate is $23.50 a share, against 2026 adjusted guidance of $19.50 to $20.00 and the $27.66 the company earned in 2024. At 17 times that gives $400. The stock is within 0.7 percent of it, which is not a call. That is the entire reason this is a HOLD rather than something more interesting.

The arithmetic inside the guidance

The most important number in this report is one the company did not print. It is implied by two it did.

The medical care ratio is the share of premium revenue paid out as medical costs, and it is the single variable that decides whether a health insurer earns anything. UnitedHealth reported 83.9% in the first quarter and 86.7% in the second, an average of 85.3%. Full-year guidance is 88.1% plus or minus 25 basis points.

Those two facts fix the third. To average 88.1% across the year having run 85.3% in the first half, the second half has to come in near 90.9%. That is a deterioration of 560 basis points against the first half, built into management's own outlook. Management said separately that UnitedHealthcare earnings are more than 75 percent weighted to the first half, which is the same statement made a different way.

The practical consequence: anyone annualizing first-half earnings is not slightly wrong. They are wrong in the optimistic direction, and by a lot. This is the denominator problem in its live form. The earnings you divide by are an output of where you happen to be standing in the year.

Earnings quality points the same way. The second quarter ratio of 86.7% includes $860 million of net favorable prior period development. Reserve releases are real money, but they are not a run rate. Using UnitedHealthcare premium revenue as the denominator, backing the release out puts the underlying ratio nearer 87.7%. A company that needs that much favorable development to produce the improvement is telling you something about the underlying rate.

What counts as normal

Everything about this valuation turns on one question, and it is not a question about UnitedHealth's quality. It is a question about which year to believe.

We do not think 27.66 is the right normal. Adjusted earnings fell 40.9% from 2024 to 2025, and the medical care ratio rose 340 basis points. The causes are structural rather than transitory: Medicare Advantage utilization normalizing after the pandemic, the V28 risk model phasing in, Medicaid redeterminations leaving a worse risk pool, and Medicaid rate updates running at 6 to 7 percent against a medical trend management describes as running ahead of them. Those do not reverse because a management team would like them to.

Nor do we think $19.75 is normal. Medicaid margins are guided negative for 2026, in the minus 1 to minus 1.7 percent range, and commercial sits well below the 7 percent or better management targets as a return to historic performance. Both should improve from here.

2026 guidance recovers only 30.1% of the earnings lost between 2024 and 2025. We think the eventual recovery is larger than that and smaller than a full return, which puts normalized earnings around $23.50.

On the multiple, 17 times is a modest discount to the broad market, and we think this business has earned that discount. 2025 demonstrated that these earnings can nearly halve in a single year on policy and utilization shifts largely outside the company's control. The market did not price that possibility before it happened. It should price it now.

What the price assumes

Run it backwards, the way we always do. At $397.14, the earnings required to justify the price depend on the multiple you are willing to pay.

At 17 times, today's price already assumes about $23.36 of earnings, roughly 18% more than the company guides to this year. So the market is not pricing UnitedHealth as a broken business. It is pricing in a substantial recovery that has not happened yet, while stopping well short of a full return to 2024.

That is, in our view, roughly the right assumption. Which is exactly why there is no call here.

The company is shrinking on purpose

One detail deserves more attention than it has received. In 2025 revenue grew 11.8% while reported operating earnings fell 41.3%. For 2026 the company guides revenue 1.7% lower, the first decline in a decade, as it exits members, geographies and products that do not clear its return threshold. UnitedHealthcare served 48.5 million people in the second quarter, down 525,000 sequentially.

Most coverage reads shrinking revenue as weakness. On these numbers it is the correct decision, and it is the clearest evidence that management understands the problem. Growth funded at returns below the cost of capital destroys value, and a company in that position is worth more standing still. UnitedHealth spent 2025 demonstrating the first half of that sentence. It is spending 2026 acting on the second.

We would rather own a company shrinking toward profitability than one growing away from it. That view is already reflected in our normalized earnings estimate, and it is a large part of why this is a HOLD and not a SELL.

The bull case, and why this is a HOLD

The bull case is not weak, and we want to state it properly rather than knock down a straw version.

The 2.8 billion dollar pre-tax charge taken in the fourth quarter of 2025 is behind them. It covered the final direct costs of the Change Healthcare cyberattack, divestitures including South America and European operations, restructuring, loss contract provisions, real estate and workforce reductions. Those are cleanup costs, not operating ones, and they do not recur.

Pricing discipline is visibly working: the medical care ratio improved 80 basis points year over year at the guidance level, membership is being repriced rather than defended, and operating cash flow ran at roughly 1.9 times net income in the quarter. If commercial margins reach the 7 percent management targets and Medicaid rates catch up to trend, earnings well above our normalized figure are achievable, and at 27.66 of earnings this stock is worth far more than $400.

We do not dismiss that. We simply note that it requires a sequence of things to go right, that management has told us the commercial piece will take longer than they first thought, and that the price already embeds a meaningful part of it. A stock trading 0.7 percent from our estimate of fair value does not compensate you for that sequence failing.

Equally, this is not a SELL. The franchise is intact, the balance sheet is serviceable with debt to capital at 41.2% against a roughly 40 percent target, the charges are done, and the direction of travel on margin is correct. Selling a repairing business at fair value on the theory that the repair will disappoint is a different and worse bet than the one we are declining to make.

Risks

To the downside. Second-half medical care ratio coming in above the implied 90.9%. 2027 guidance opening below roughly $22. Medicaid margins staying negative into 2027. Continued dependence on favorable prior period development to hit the ratio, which is the single number we would watch most closely. Policy risk is genuine and largely outside the company's control, as 2025 demonstrated. Regulatory and legal overhangs remain.

To the upside. Second-half ratio beating the implied figure. Commercial margins reaching 7 percent faster than guided. Optum Health recovering faster than the at least 2.2 billion dollars now guided. Any of these would move our normalized estimate up, and the fair value with it.

To our own reasoning. The largest single judgment in this report is that 2024 was not a normal year. If that is wrong, and the pre-2025 margin structure is genuinely recoverable, then normalized earnings are nearer 27.66 and fair value is nearer $470. We would be wrong by a wide margin. We think the structural explanation is better supported, but it is a judgment and not an observation, and it is the thing to attack if you disagree with this note.

Methodology, sources & disclosures

Methodology

Every figure in this report is computed by a model script rather than typed, and the script runs a self-check that reconciles the implied second-half medical care ratio back to full-year guidance. Where the company reports both adjusted and GAAP figures we use adjusted for multi-year comparison, because the 2025 charge was genuinely non-recurring, and we disclose that choice rather than leave it silent. The ex-development medical care ratio uses UnitedHealthcare premium revenue as the denominator and is a proxy, not the exact figure, which the company does not break out.

The reference price

The $397.14 reference price is the close on Friday, September 4, 2026. It was verified before any modeling against five independent sources: Yahoo Finance, timestamped at 4:00:02 PM EDT, Macrotrends, Morningstar, Robinhood and stockinvest.us, all agreeing exactly. Two discrepancies are recorded for completeness: Investing.com's quote page served a stale $400.94 that contradicts its own historical table, and Macroaxis is date-shifted by one day and lists a close for Sunday, August 30, which is not a trading day. Neither affects the verified figure.

Primary sources

Second quarter 2026 results and guidance from the Form 8-K filed July 16, 2026; first quarter 2026 results from the Form 8-K filed April 21, 2026; full year 2025 results and the initial 2026 outlook from the company's results release of January 27, 2026. Company filings and investor materials read directly at unitedhealthgroup.com investors; filings as submitted via SEC EDGAR.

Scoring

This call is dated and public. It joins the scoreboard as an open position at $397.14 and will be scored against the S&P 500 on the same terms as every other call we have made, whether it works or not. Our standing view on hit rates applies: a record this short proves nothing either way.